Apollo Drug Discovery Team

Home  /  Apollo People  /  Dr Tony Hickson
Tony Hickson

DR TONY HICKSON BSc, MBA, CLP, RTTP

Managing Director, Technology Transfer & Executive Director Imperial Innovations Group PLC

Tony Hickson BSc, MBA, CLP, RTTP is Managing Director of the Technology Transfer team and an Executive Director on the board of Imperial Innovations Group PLC. Tony is responsible for intellectual property sourcing, licensing and spin-out creation for technologies arising from Imperial College London. Prior to joining the company in 2002, Tony had acquired 15 years of commercial and business development experience in bioscience companies including Wellcome Group, Murex Biotech, Abbott Laboratories and Kalibrant Limited. He has been a board director or observer for a number of start-up companies including Emcision, Polytherics (now Abzena) and Catapult Therapy TCR Limited, and was instrumental in the creation of companies such as Thiakis (sold to Wyeth, now Pfizer, in 2008), Respivert (sold to J&J in 2010), Circassia (floated on LSE in 2014) and Cell Medica (in advanced clinical studies). Tony is a Certified Licensing Professional, a board director of PraxisUnico and until recently acted as Chairman of the Intellectual Property Board of the European Institute of Technology Climate Change KIC.

Apollo aims to integrate academic research
and the biopharma industry